Olaparib Gains BRCA-Mutated Prostate Cancer Indication Olaparib Gains BRCA-Mutated Prostate Cancer Indication
The new indication adds to the PARP inhibitor ' s previous approvals for HRR-mutated metastatic castration-resistant prostate cancer as well as for ovarian, breast, and pancreatic cancer indications.Medscape Medical News
Source: Medscape Urology Headlines - Category: Urology & Nephrology Tags: Hematology-Oncology News Alert Source Type: news
More News: Cancer | Cancer & Oncology | Hematology | Ovarian Cancer | Ovaries | Pancreas | Pancreatic Cancer | Prostate Cancer | Urology & Nephrology